M J Domanski

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Geographic variability in patient characteristics, treatment and outcome in an International Trial of Magnesium in acute myocardial infarction
    Michael Domanski
    The Clinical Trials Group, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, MSC 7936, Bethesda, MD 20892, USA
    Control Clin Trials 25:553-62. 2004
  2. ncbi Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 42:705-8. 2003
  3. ncbi The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
  4. ncbi Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. The Balloon Angioplasty Revascularization Investigation (BARI)
    M J Domanski
    Clinical Trials Group, Divison of Epidemiology and Clinical Applications, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    Am J Cardiol 87:675-9. 2001
  5. ncbi Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventric
    D L Dries
    Clinical Trials Scientific Research Group, The National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 32:695-703. 1998
  6. ncbi Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction
    M J Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 33:951-8. 1999
  7. ncbi Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction
    D V Exner
    Clinical Trials Scientific Research Group, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 33:916-23. 1999
  8. ncbi Racial differences in the outcome of left ventricular dysfunction
    D L Dries
    Clinical Trials Scientific Research Group, Division of Epidemiology and Clinical Application, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 7936, USA
    N Engl J Med 340:609-16. 1999
  9. ncbi Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction)
    H Rashid
    Clinical Trials Research Group and Office of Biostatistics Research, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA
    Am J Cardiol 84:299-303. 1999
  10. ncbi Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials
    D L Dries
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 29:1074-80. 1997

Detail Information

Publications31

  1. ncbi Geographic variability in patient characteristics, treatment and outcome in an International Trial of Magnesium in acute myocardial infarction
    Michael Domanski
    The Clinical Trials Group, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, MSC 7936, Bethesda, MD 20892, USA
    Control Clin Trials 25:553-62. 2004
    ..This study examined the regional differences in baseline characteristics, treatment, and outcome in patients presenting with ST elevation myocardial infarction (STEMI) who were entered into the Magnesium in Coronaries (MAGIC) trial...
  2. ncbi Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 42:705-8. 2003
    ..We sought to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a PSD may result in progressive heart failure (HF)...
  3. ncbi The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
    ..This was a retrospective analysis to determine the effect of diabetes on outcome in patients with advanced heart failure (HF), and to determine the effect of beta-blockade in patients with HF with and without diabetes mellitus...
  4. ncbi Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. The Balloon Angioplasty Revascularization Investigation (BARI)
    M J Domanski
    Clinical Trials Group, Divison of Epidemiology and Clinical Applications, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    Am J Cardiol 87:675-9. 2001
    ..After coronary revascularization, PP, reflecting arterial stiffness, is independently associated with total mortality...
  5. ncbi Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventric
    D L Dries
    Clinical Trials Scientific Research Group, The National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 32:695-703. 1998
    ....
  6. ncbi Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction
    M J Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 33:951-8. 1999
    ..The purpose of this study was to evaluate the relationship of baseline pulse pressure and mean arterial pressure to mortality in patients with left ventricular dysfunction...
  7. ncbi Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction
    D V Exner
    Clinical Trials Scientific Research Group, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 33:916-23. 1999
    ....
  8. ncbi Racial differences in the outcome of left ventricular dysfunction
    D L Dries
    Clinical Trials Scientific Research Group, Division of Epidemiology and Clinical Application, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 7936, USA
    N Engl J Med 340:609-16. 1999
    ..Although these factors probably account for some of the higher mortality due to congestive heart failure among blacks, we hypothesized that racial differences in the natural history of left ventricular dysfunction might also have a role...
  9. ncbi Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction)
    H Rashid
    Clinical Trials Research Group and Office of Biostatistics Research, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA
    Am J Cardiol 84:299-303. 1999
    ..These data suggest that EF values determined by echocardiography and radionuclide angiography predict different mortality and this may, in part, be related to technical proficiency as well as patient characteristics...
  10. ncbi Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials
    D L Dries
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 29:1074-80. 1997
    ....
  11. ncbi Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
    H A Cooper
    Clinical Trials Scientific Research Group, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Circulation 100:1311-5. 1999
    ..These data suggest that diuretic-induced electrolyte disturbances may result in fatal arrhythmias in patients with systolic left ventricular dysfunction...
  12. ncbi White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD])
    H A Cooper
    Clinical Trials Scientific Research Group, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA
    Am J Cardiol 84:252-7. 1999
    ..08, p = 0.5). Thus, baseline WBC is an independent predictor of mortality in patients with LV dysfunction, specifically in those with ischemic cardiomyopathy...
  13. ncbi Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials
    M J Domanski
    Clinical Trials Group, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 33:598-604. 1999
    ..Estimate the effect of angiotensin converting enzyme (ACE) inhibitors on the risk of sudden cardiac death (SCD) following myocardial infarction (MI)...
  14. ncbi Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction
    H A Cooper
    Clinical Trials Research Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    J Am Coll Cardiol 35:1753-9. 2000
    ..The study evaluated the relationship between light-to-moderate alcohol consumption and prognosis in patients with left ventricular (LV) systolic dysfunction...
  15. ncbi Isolated systolic hypertension : prognostic information provided by pulse pressure
    M J Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 7936, USA
    Hypertension 34:375-80. 1999
    ....
  16. ncbi beta-blockers in heart failure: recently completed and ongoing clinical trials
    D McAreavey
    Clinical Trials Research, National Heart, Lung and Blood Institute, 6701 Rockledge Drive, Room 8146, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 9:415-28. 2000
    ..Finally, ongoing trials designed to assess the relative efficacy of different beta-blockers and evaluate the utility of beta-blockade in specific subsets of patients with heart failure are discussed...
  17. ncbi Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST])
    Michael Domanski
    Atherothrombosis and Coronary Artery Disease Branch, Division of Cardiovascular Disease, National Heart, Lung, and Blood Institute NIH, Bethesda, MD 20892, USA
    Am J Cardiol 99:1448-50. 2007
    ..18 to 0.95, p = 0.037). In conclusion, in patients with moderate or severe HF due to non-IDC entered into BEST, statin therapy at entry was independently associated with a decrease in all-cause and cardiovascular mortality...
  18. ncbi Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)
    Emily Y Chew
    Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 1204, USA
    Am J Cardiol 99:103i-111i. 2007
    ..These data will provide valuable information regarding the effects of medical treatment on the prevention and progression of DR...
  19. ncbi Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Denise E Bonds
    Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Am J Cardiol 99:80i-89i. 2007
    ..In addition, translation of the principles behind the monitoring of severe hypoglycemia in ACCORD into feasible strategies for use in clinical practice will be needed...
  20. ncbi Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial
    Michael E Farkouh
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Am Heart J 155:215-23. 2008
    ..The FREEDOM Trial is designed to determine whether CABG or percutaneous coronary intervention (PCI) is the superior approach for revascularization of diabetic patients...
  21. ncbi Diuretic use, progressive heart failure, and death in patients in the DIG study
    Michael Domanski
    Clinical Trials Group, Blood Institute, Bethesda, Maryland, USA
    J Card Fail 12:327-32. 2006
    ..71, 95% CI 0.52-0.96, P = .02). CONCLUSION: NPSDs are associated with increased risk of death, CVD, progressive HF death, SCD, and HF hospitalization. A randomized trial is needed to assess the role of NPSDs versus PSDs in HF patients...
  22. ncbi Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial
    Michael Domanski
    Atherothrombosis and Coronary Artery Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    Am J Cardiol 102:1023-7. 2008
    ..343 mm, p = 0.042). In conclusion, aggressive versus moderate lovastatin treatment appeared therapeutic in slowing the atherosclerotic process in SVGs from Post CABG patients, independent of its greater LDL cholesterol-lowering effect...
  23. ncbi Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Gust H Bardy
    Seattle Institute for Cardiac Research, Seattle, WA 98103, USA
    N Engl J Med 352:225-37. 2005
    ..Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients...
  24. ncbi Angiographic changes in saphenous vein grafts are predictors of clinical outcomes
    Genell L Knatterud
    Maryland Medical Research Institute, Baltimore, MD 21210, USA
    Am Heart J 145:262-9. 2003
    ..6 mm in lumen diameter at site of greatest change from baseline)...
  25. ncbi Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population
    Eliot Peyster
    The Clinical Trials Group, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute/NIH, Two Rockledge Center, 6701 Rockledge Drive, MSC 7936, Bethesda, MD 20892, USA
    J Card Fail 10:49-54. 2004
    ..Although there was an independent association of PSF HF with a number of clinical characteristics, none of these characteristics was pathognomonic of preserved, versus reduced, systolic function HF...
  26. ncbi Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
    Am Heart J 153:951-9. 2007
    ....
  27. ncbi Frequency of aspirin resistance in a community hospital
    Ahmadshah Mirkhel
    Department of Internal Medicine, Prince Georges Hospital Center, Cheverly, Maryland, USA
    Am J Cardiol 98:577-9. 2006
    ..Nonresponders to 81 mg/day frequently responded to 325 mg/day or to the addition of clopidogrel...
  28. ncbi Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:26-31. 2006
    ..In the post-myocardial infarction setting, angiotensin-converting enzyme (ACE) inhibitors have been shown to be as effective in patients with impaired renal function as in those with preserved renal function...
  29. ncbi Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2687-93. 2007
    ..We assessed the association between albuminuria and the risks for death and cardiovascular events among patients with stable coronary disease...
  30. ncbi Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT)
    Michael Domanski
    Division of Biostatistics, School of Public Health, 2221 University Ave SE, Room 200, Minneapolis, MN 55414, USA
    JAMA 287:2677-83. 2002
    ..CONCLUSION: In both age groups, cardiovascular disease risk assessment was improved by considering both SBP and DBP, not just SBP, DBP, or pulse pressure separately...
  31. ncbi Prognosis in atrial fibrillation
    Michael Domanski
    Eur Heart J 27:895-6. 2006